(Q29617779)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16915295%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

review article

1 reference

title

mTOR and cancer: insights into a complex relationship (English)

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16915295

30 April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16915295%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1

Sabatini DM

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16915295%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16915295

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16915295

30 April 2017

language of work or name

1 reference

30 April 2017

publication date

17 August 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16915295%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

published in

Nature Reviews Cancer

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16915295

30 April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16915295%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

volume

6

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16915295

30 April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16915295%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

page(s)

729-734

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16915295%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

issue

9

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16915295

30 April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16915295%20AND%20SRC:MED&resulttype=core&format=json

Growing roles for the mTOR pathway

28 December 2019

cites work

1 reference

The Drosophila tuberous sclerosis complex gene homologs restrict cell growth and cell proliferation.

31 March 2020

1 reference

Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling

31 March 2020

1 reference

Rheb promotes cell growth as a component of the insulin/TOR signalling network

31 March 2020

1 reference

Rheb is an essential regulator of S6K in controlling cell growth in Drosophila

31 March 2020

1 reference

Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins

31 March 2020

1 reference

Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb

31 March 2020

1 reference

Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2

31 March 2020

1 reference

Rheb binds and regulates the mTOR kinase

31 March 2020

1 reference

TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

31 March 2020

1 reference

Akt regulates growth by directly phosphorylating Tsc2

31 March 2020

1 reference

Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway

31 March 2020

1 reference

Inactivation of the tuberous sclerosis complex-1 and -2 gene products occurs by phosphoinositide 3-kinase/Akt-dependent and -independent phosphorylation of tuberin

31 March 2020

1 reference

The NF1 tumor suppressor critically regulates TSC2 and mTOR.

31 March 2020

1 reference

The coordinate regulation of the p53 and mTOR pathways in cells

31 March 2020

1 reference

The LKB1 tumor suppressor negatively regulates mTOR signaling

31 March 2020

1 reference

Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome

31 March 2020

1 reference

TSC2 mediates cellular energy response to control cell growth and survival

31 March 2020

1 reference

Upstream and downstream of mTOR

31 March 2020

1 reference

Mammalian target of rapamycin pathway regulates insulin signaling via subcellular redistribution of insulin receptor substrate 1 and integrates nutritional signals and metabolic signals of insulin

31 March 2020

1 reference

A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1.

31 March 2020

1 reference

The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins

31 March 2020

1 reference

Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies

31 March 2020

1 reference

Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression

31 March 2020

1 reference

Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2

31 March 2020

1 reference

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

31 March 2020

1 reference

mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes

31 March 2020

1 reference

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

31 March 2020

1 reference

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

31 March 2020

1 reference

mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery

31 March 2020

1 reference

Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action

31 March 2020

1 reference

TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function

31 March 2020

1 reference

The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif

31 March 2020

1 reference

An expanding role for mTOR in cancer

31 March 2020

1 reference

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

31 March 2020

1 reference

mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s

31 March 2020

1 reference

Regulation of microtubule-dependent protein transport by the TSC2/mammalian target of rapamycin pathway.

31 March 2020

1 reference

The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL

31 March 2020

1 reference

Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells

31 March 2020

1 reference

Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells

31 March 2020

1 reference

The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.

31 March 2020

1 reference

Cell size reduction induced by inhibition of the mTOR/S6K-signaling pathway protects Jurkat cells from apoptosis

31 March 2020

1 reference

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

31 March 2020

1 reference

Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.

31 March 2020

1 reference

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

31 March 2020

1 reference

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma

31 March 2020

1 reference

Rapamycin causes regression of astrocytomas in tuberous sclerosis complex

31 March 2020

1 reference

Tuberous sclerosis genes regulate cellular 14-3-3 protein levels

31 March 2020

1 reference

The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho

31 March 2020

1 reference

Identification and characterization of RHEBL1, a novel member of Ras family, which activates transcriptional activities of NF-kappa B

31 March 2020

1 reference

Novel role of the small GTPase Rheb: its implication in endocytic pathway independent of the activation of mammalian target of rapamycin

31 March 2020

1 reference

Regulation of B-Raf kinase activity by tuberin and Rheb is mammalian target of rapamycin (mTOR)-independent

31 March 2020

1 reference

Rheb interacts with Raf-1 kinase and may function to integrate growth factor- and protein kinase A-dependent signals

31 March 2020

1 reference

Rheb inhibits C-raf activity and B-raf/C-raf heterodimerization

31 March 2020

1 reference

Regulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2

31 March 2020

1 reference

Mutations in the PI3K/PTEN/TSC2 pathway contribute to mammalian target of rapamycin activity and increased translation under hypoxic conditions

31 March 2020

1 reference

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

31 March 2020

1 reference

An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice

31 March 2020

1 reference

mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

31 March 2020

1 reference

Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy

31 March 2020

1 reference

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer

31 March 2020

1 reference

Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.

31 March 2020

1 reference

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

31 March 2020

1 reference

A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma

31 March 2020

1 reference

A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling

31 March 2020

1 reference

Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation

31 March 2020

1 reference

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

31 March 2020

1 reference

Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma

31 March 2020

1 reference

Sirolimus for Kaposi's sarcoma in renal-transplant recipients

31 March 2020

1 reference

Targeted inhibition of angiogenic factors in AIDS-related disorders

31 March 2020

1 reference

Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin.

31 March 2020

1 reference

Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

31 March 2020

1 reference

Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus

31 March 2020

1 reference

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

31 March 2020

1 reference

Rapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer

31 March 2020

1 reference

Role of Akt signaling in vascular homeostasis and angiogenesis

31 March 2020

1 reference

Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes

31 March 2020

1 reference

Biology and therapy of mantle cell lymphoma

31 March 2020

1 reference

Cyclin D Expression Is Controlled Post-transcriptionally via a Phosphatidylinositol 3-Kinase/Akt-dependent Pathway

31 March 2020

1 reference

G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells

31 March 2020

1 reference

Rapamycin disrupts cyclin/cyclin-dependent kinase/p21/proliferating cell nuclear antigen complexes and cyclin D1 reverses rapamycin action by stabilizing these complexes.

31 March 2020

1 reference

Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability

31 March 2020

1 reference

Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma

31 March 2020

1 reference

Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development

31 March 2020

1 reference

mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells

31 March 2020

1 reference

Activity of rapamycin (AY-22,989) against transplanted tumors

31 March 2020

1 reference

GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR

31 March 2020

1 reference

Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control

31 March 2020

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16915295

31 March 2020

Identifiers

3 references

30 April 2017

Consolidated OpenCitations Corpus – April 2017

276683

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16915295%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

28 December 2019

1037215968

0 references

276683

1 reference

Consolidated OpenCitations Corpus – April 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=16915295

3 references

30 April 2017

Consolidated OpenCitations Corpus – April 2017

276683

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16915295%20AND%20SRC:MED&resulttype=core&format=json